Research programme: encapsulated skin cancer therapeutics - Aphios

Drug Profile

Research programme: encapsulated skin cancer therapeutics - Aphios

Alternative Names: APH-0201; Betulinic acid nanosomes/nanospheres - Aphios; Dermos; Nanosomal paclitaxel - Aphios; Nanosome/nanosphere skin cancer therapeutics - Aphios

Latest Information Update: 17 Oct 2014

Price : $50

At a glance

  • Originator Aphios Corporation
  • Class Lipoproteins; Triterpenes
  • Mechanism of Action Apoprotein stimulants; Caspase stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Malignant melanoma; Skin cancer

Highest Development Phases

  • Preclinical Malignant melanoma; Skin cancer

Most Recent Events

  • 17 Oct 2014 Preclinical development in Malignant melanoma is ongoing in the US
  • 17 Oct 2014 Dermos™ and APH 0201 (Betulinic acid) are available for licensing - http://www.aphios.com/products/therapeutic-product-pipeline/oncology/dermos.html
  • 10 Jul 2009 Preclinical (pre-IND) development of Dermos™ is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top